Analyst Ratings for Mirum Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Mirum Pharmaceuticals (NASDAQ:MIRM) has received 9 bullish ratings from analysts in the last quarter, with an average 12-month price target of $67.33, a decrease of 10.62% from the previous average price target of $75.33. No bearish or indifferent ratings were observed.
November 03, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have given Mirum Pharmaceuticals a bullish rating, with a 12-month price target of $67.33, a decrease from the previous target.
The bullish ratings from analysts indicate a positive outlook for Mirum Pharmaceuticals. However, the decrease in the price target may suggest a potential slowdown in growth or other factors that could impact the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100